Capacity Expansion And Complex APIs Will Drive Long Term Earnings Power

Catalysts

About Alivus Life Sciences

Alivus Life Sciences is a specialty pharmaceutical ingredients and CDMO company focused on complex, high value APIs and partnered development for global regulated markets.

What are the underlying business or industry changes driving this perspective?

• Expansion of capacity at Solapur, Ankleshwar and Dahej, including continuous manufacturing and backward integration, positions Alivus to capture rising global API demand, supporting higher revenue growth and operating leverage driven improvement in EBITDA margins.
• A growing pipeline of 586 DMF and CEP filings, together with 26 high potent APIs targeting a USD 66 billion market, increases the mix of complex, premium products, which should sustain pricing power and enhance gross margins and earnings quality over time.
• Broad based recovery in GPL and a stronger CDMO ramp with five commercial projects expected to be active, leverages fixed assets and R&D already in place, which can lift utilization, expand EBITDA margins and accelerate earnings growth without commensurate CapEx.
• Deeper penetration in Japan, LATAM, Europe and emerging markets, driven by multiple new launches per year and API plus value added services, taps structurally rising chronic and specialty medicine consumption, which should diversify revenue and stabilize net margins across cycles.
• Disciplined CapEx deployment, a net debt free balance sheet and more than INR 650 crores of cash enable selective API plus and inorganic opportunities, which can add high return growth engines and support a sustained uplift in return on capital employed and long term earnings.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Alivus Life Sciences's revenue will grow by 12.5% annually over the next 3 years.
• Analysts assume that profit margins will increase from 23.3% today to 28.2% in 3 years time.
• Analysts expect earnings to reach ₹10.4 billion (and earnings per share of ₹71.11) by about September 2029, up from ₹6.0 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting ₹12.9 billion in earnings, and the most bearish expecting ₹9.1 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.1x on those 2029 earnings, down from 28.9x today. This future PE is lower than the current PE for the IN Pharmaceuticals industry at 31.0x.
• Analysts expect the number of shares outstanding to grow by 0.07% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 12.44%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The management expectation of GPL and CDMO recovery in the second half assumes customer inventory normalization and regulatory approvals arriving on time. If global pharma customers prolong destocking or delay project scale up, Alivus could see slower volume growth and softer realizations, pressuring revenue and EBITDA.
• API pricing for more mature and commoditized molecules is already described as stable to slightly declining. If a prolonged benign or deflationary environment for finished dosages and raw materials persists, Alivus may need to sacrifice price to defend share, which would weigh on gross margins and earnings despite higher volumes.
• The company is committing large multi year CapEx at Solapur, Ankleshwar and Dahej while also evaluating inorganic API plus opportunities. If end market demand or CDMO conversion lags the new capacity, returns on invested capital could fall and underutilization would dilute EBITDA margins and net profit.
• Working capital intensity remains high with receivables around 148 days and total working capital above INR 1,300 crores. If customer payment cycles lengthen further or inventories rise to support new launches and geographic expansion, cash generation per unit of earnings could deteriorate, constraining the ability to fund growth without impacting net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of ₹1432.25 for Alivus Life Sciences based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of ₹1624.0, and the most bearish reporting a price target of just ₹1330.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be ₹36.9 billion, earnings will come to ₹10.4 billion, and it would be trading on a PE ratio of 24.1x, assuming you use a discount rate of 12.4%.
• Given the current share price of ₹1417.9, the analyst price target of ₹1432.25 is 1.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.